Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2832-2839

  Raida, Martin ^a   Höffken, Klaus ^a   Schwabe, Wolfgang ^b   Häusler, Peter ^b   Behnke, Detlev ^b   Van Kuilenburg, Andre B P ^c   Van Gennip, Albert H ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Oncoscreen GmbH   (Germany)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME DEFICIENCY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR;

ADULT; AGED; ALTERNATIVE SPLICING; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COLONIC NEOPLASMS; DIARRHEA; DIHYDROURACIL DEHYDROGENASE (NADP); DNA, COMPLEMENTARY; EXONS; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INTRONS; LEUKOPENIA; MALE; MIDDLE AGED; OXIDOREDUCTASES; POINT MUTATION; RECTAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS; STOMATITIS; THROMBOCYTOPENIA;

EID: 0034808681     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Biochemical and clinical pharmacology of 5-flourouracil
2. Biomodulation of cancer chemotherapy
3. 5-Fluorouracil pharmacokinetics: Causes for viability and strategies for modulation in cancer chemotherapy
4. 5-Fluoropyrimidines
5. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
6. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
7. Correlation between dihydropyrimidine debydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
8. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity
9. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome
10. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
11. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
12. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
13. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
14. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria
15. Structural organization of the human dihydropyrimidine dehydrogenase gene
16. Characterization of the human dihydropyrimidine dehydrogenase gene
17. Human polymorphism in drug metabolism: Mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uraciluria
18. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
19. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency
20. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
21. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity
22. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil
23. Optimisation of DNA and RNA extraction from archival formalin-fixed tissue
24. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
25. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples
26. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction
27. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species
28. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency
29. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
30. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity
31. Mutations at codon 974 of the DPYD gene are a rare event